Abstract:Currently licensed glycoconjugate vaccines are composed of a carbohydrate moiety covalently linked to a protein carrier. Polysaccharides are T-cell independent antigens able to directly stimulate B cells to produce antibodies. Disease burden caused by polysaccharide-encapsulated bacteria is highest in the first year of life, where plain polysaccharides are not generally immunogenic, limiting their use as vaccines. This limitation has been overcome by covalent coupling carbohydrate antigens to proteins that provide T cell epitopes. In addition to the protein carriers currently used in licensed glycoconjugate vaccines, there is a search for new protein carriers driven by several considerations: (i) concerns that pre-exposure or co-exposure to a given carrier can lead to immune interference and reduction of the anti-carbohydrate immune response; (ii) increasing interest to explore the dual role of proteins as carrier and protective antigen; and (iii) new ways to present carbohydrates antigens to the immune system. Protein carriers can be directly coupled to activated glycans or derivatized to introduce functional groups for subsequent conjugation. Proteins can be genetically modified to pre-determine the site of glycans attachment by insertion of unnatural amino acids bearing specific functional groups, or glycosylation consensus sequences for in vivo expression of the glycoconjugate. A large portion of the new protein carriers under investigation are recombinant ones, but more complex systems such as Outer Membrane Vesicles and other nanoparticles are being investigated. Selection criteria for new protein carriers are based on several aspects including safety, manufacturability, stability, reactivity toward conjugation, and preclinical evidence of immunogenicity of corresponding glycoconjugates. Characterization panels of protein carriers include tests before conjugation, after derivatization when applicable, and after conjugation. Glycoconjugate vaccines based on non-covalent association of carrier systems to carbohydrates are being investigated with promising results in animal models. The ability of these systems to convert T-independent carbohydrate antigens into T-dependent ones, in comparison to traditional glycoconjugates, needs to be assessed in humans.

Carbohydrates as putative pattern recognition receptor agonists in vaccine development

Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action

Facile Preparation of Carbohydrate‐Containing Adjuvants Based on Self‐Assembling Glycopeptide Conjugates

A Toll-like Receptor-Activating, Self-Adjuvant Glycan Nanocarrier

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases

A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines

Synthesis and immunological evaluation of a low molecular weight saccharide with TLR-4 agonist activity

The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine

Polysaccharides derived from Chinese medicinal herbs: A promising choice of vaccine adjuvants

Glycodendrimers as functional antigens and antitumor vaccines

In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives

Chemical Synthesis of Glycans and Applications in Carbohydrate-Based Vaccines

Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy

Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends

A Comparative Study on the Mechanisms of Innate Immune Responses in Mice Induced by Alum and Actinidia Eriantha Polysaccharide.

Adjuvant effect of two polysaccharides from the petals of Crocus sativus and its mechanisms

Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions

Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach

Modular Platform of Carbohydrates-modified Supramolecular Polymers Based on Dendritic Peptide Scaffolds

[Recent Advance in Carbohydrate-Based Cancer Vaccines].

Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants